Bowel hot spots at PET-CT

Radiographics

Volumn 27, Issue 1, 2007, Pages 145-159

  Prabhakar, Hima B ^a   Sahani, Dushyant V ^a   Fischman, Alan J ^a   Mueller, Peter R ^a   Blake, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; ENTEROPATHY; HUMAN; IMAGE ENHANCEMENT; IMAGE SUBTRACTION; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; REVIEW;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; INTESTINAL DISEASES; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33847075920     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.271065080     Document Type: Review

References (39)

1. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. RadioGraphics 2004;24:1411-1431.
2. Kresnik E, Mikosch P, Gallowitsch HJ, Heinisch M, Lind P. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory bowel disease. Clin Nucl Med 2001;26:867.
3. Skehan SJ, Issenman R, Mernagh J, Nahmias C, Jacobson K. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 1999;354:836-837.
4. Bicik I, Bauerfeind P, Breitbach T, von Schulthess GK, Fried M. Inflammatory bowel disease activity measured by positron-emission tomography. Lancet 1997;350:262.
5. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755-760.
6. Kim JH, Czernin J, Allen-Auerbach MS, et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005;46:587-595.
7. Larson SM, Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 2004;10:243-250.
8. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-885.
9. Groves AM, Kayani I, Dickson JC, et al. Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imaging 2005;32:1160-1166.
10. Hausegger K, Reinprecht P, Kau T, Igerc I, Lind P. Clinical experience with a commercially available negative oral contrast medium in PET/CT. Rofo 2005;177:796-799.
11. Otsuka H, Graham MM, Kubo A, Nishitani H. The effect of oral contrast on large bowel activity in FDG-PET/CT. Ann Nucl Med 2005;19:101-108.
12. Abouzied MM, Crawford ES, Nabi HA. 18FFDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145-155.
13. Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002;224:783-787.
14. Bural GG, Kumar R, Mavi A, Alavi A. Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET. Clin Nucl Med 2005;30:182-183.
15. Bhargava P, Reich P, Alavi A, Zhuang H. Radiation-induced esophagitis on FDG PET imaging. Clin Nucl Med 2003;28:849-850.
16. Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004;45:1804-1810.
17. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. RadioGraphics 2000;20:713-723.
18. Ba-Ssalamah A, Prokop M, Uffmann M, Pokieser P, Teleky B, Lechner G. Dedicated multidetector CT of the stomach: spectrum of diseases. RadioGraphics 2003;23:625-644.
19. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nucl Med 1999;24:281-282.
20. Ak I, Gulbas Z. Intense F-18 FDG accumulation in stomach in a patient with Hodgkin lymphoma: Helicobacter pylori infection as a pitfall in oncologic diagnosis with F-18 FDG PET imaging. Clin Nucl Med 2005;30:41.
21. Lim JS, Yun MJ, Kim MJ, et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. RadioGraphics 2006;26:143-156.
22. McAteer D, Wallis F, Couper G, et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999;72:525-529.
23. Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 2003;44:690-699.
24. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-365.
25. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153-162.
26. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. RadioGraphics 2005;25:1031-1043.
27. Wittenberg J, Harisinghani MG, Jhaveri K, Varghese J, Mueller PR. Algorithmic approach to CT diagnosis of the abnormal bowel wall. RadioGraphics 2002;22:1093-1109.
28. Mahfouz T, Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol 2005;23:7857-7863.
29. Neurath MF, Vehling D, Schunk K, et al. Non-invasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002;97:1978-1985.
30. Lemberg DA, Issenman RM, Cawdron R, et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005;11:733-738.
31. Tatlidil R, Mandelkern M. FDG-PET in the detection of gastrointestinal metastases in melanoma. Melanoma Res 2001;11:297-301.
32. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332.
33. Israel O, Yefremov N, Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005;46:758-762.
34. Pandit-Taskar N, Schoder H, Gonen M, Larson SM, Yeung HW. Clinical significance of unexplained abnormal focal FDG uptake in the abdomen during whole-body PET. AJR Am J Roentgenol 2004;183:1143-1147.
35. Kresnik E, Gallowitsch HJ, Mikosch P, et al. (18)F-FDG positron emission tomography in the early diagnosis of enterocolitis: preliminary results. Eur J Nucl Med Mol Imaging 2002;29:1389-1392.
36. Lardinois D, Weder W, Roudas M, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol 2005;23:6846-6853.
37. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. RadioGraphics 2003;23:315-340.
38. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001;28:1766-1769.
39. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005;185:495-500.